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Abstract
Background: Scattered extracellular deposits of amyloid within the brain parenchyma can be found in a
heterogeneous group of diseases. Its condensed accumulation in the white matter without evidence for systemic
amyloidosis is known as primary brain amyloidoma (PBA). Although originally considered as a tumor-like lesion by
its space-occupying effect, this condition displays also common hallmarks of a neurodegenerative disorder.
Case presentation: A 50-year-old woman presented with a mild cognitive decline and seizures with a right
temporal, irregular and contrast-enhancing mass on magnetic resonance imaging. Suspecting a high-grade glioma,
the firm tumor was subtotally resected. Neuropathological examination showed no glioma, but distinct features of
a neurodegenerative disorder. The lesion was composed of amyloid AL λ aggregating within the brain parenchyma
as well as the adjacent vessels, partially obstructing the vascular lumina. Immunostaining confirmed a distinct
perivascular inflammatory reaction. After removal of the PBA, mnestic impairments improved considerably, the
clinical course and MRI-results are stable in the 8-year follow-up.
Conclusion: Based on our histopathological findings, we propose to regard the clinicopathological entity of PBA as
an overlap between a neoplastic and neurodegenerative disorder. Since the lesions are locally restricted, they might
be amenable to surgery with the prospect of a definite cure.
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Background
Primary brain amyloidoma (PBA) is a rare tumor-like le-
sion characterized by a condensed deposition of amyloid
within the brain parenchyma without evidence for sys-
temic amyloidosis. PBA was originally reported by Salty-
kow in 1935 [1] followed by almost 40 additional cases
with an average age of the patients at diagnosis of 49
(15–71) years [2]. However, the actual incidence of the
condition is unknown. In almost all cases, the amyloid
accumulations were found exclusively in the white mat-
ter of different supratentorial brain regions, predomin-
antly in the frontal lobe and in proximity to the
ventricular system [3, 4]. As neuroimaging features are
multifaceted - except the disruption of the
blood-brain-barrier (BBB) as the solely consistent finding
- PBA was denominated a “chameleon-like lesion” due
to the mimicking of different brain pathologies [3].
Apart from their neoplastic phenotype, as a slowly grow-
ing mass lesion, PBA’s are part of a complex group of
progressive neurodegenerative disorders associated with
an extracellular accumulation of fibrillar amyloid aggre-
gates including, e.g., congophilic angiopathy and Alzhei-
mer’s disease. Although composed of different precursor
molecules, all cerebral amyloid deposition disorders en-
tail common clinical symptoms, i.e., cognitive deficits,
dementia, seizures, stroke, focal neurological signs, or a
combination thereof [4].
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Case presentation
This 50-year-old female patient complained of a slow
decline of her cognitive speed over several months and
became symptomatic with generalized seizures. Her pre-
vious history revealed a myocardial infarction at the age
of 42 years. Computerized tomography (CT) and mag-
netic resonance imaging (MRI) of the head showed a
right temporal mass with focal calcifications, moderate
perifocal edema and a reticulated contrast enhancement
comprising neo- and allocortical regions (Fig. 1). Sus-
pecting a high-grade glioma with an oligodendroglial
component, the tumor was resected subtotally. Unex-
pectedly, the intraoperative finding was a firm, partially
calcified and pink to greyish mass that was hypovascu-
larized and poorly demarcated, so that no clear resection
border could be defined intraoperatively.
Postoperatively, the patient recovered well, displayed a
gradual cognitive improvement during the 24-month
follow-up. She kept seizure-free under antiepileptic
medication to date during the 8-year follow-up. MRI did
not show any recurrence so far.
Neuropathological findings
Neuropathological examination showed no evidence of a
glioma, but instead neuroectodermal tissue interspersed
with scattered accumulations of periodic acid-Schiff
(PAS)-positive, amorphous material located in the extra-
cellular space that showed a distinct association to blood
vessels where it assembled in a shell-like fashion. Congo
Red staining clearly visualized extracellular amyloid de-
posits displaying apple-green birefringence under polarized
light (Fig. 2a). Immunohistochemical analysis revealed ag-
gregated λ-light chain (AL) amyloid with thioflavin
S-stained β-pleated sheet conformation (Fig. 3A to A´´).
In addition to the space-occupying effect of the widespread
extracellular amyloid deposits, a marked dissociation of
the vessel walls with subsequent stenosis (Fig. 1a) and even
total obstruction of the vascular lumina became apparent
(Fig. 3B to B´´´). Furthermore, the lesion was characterized
by a distinct perivascular inflammatory reaction compris-
ing of macrophages (Fig. 2b), microglia and T-lymphocytes
(Fig. 2c), but also scattered B-lymphocytes and plasma
cells (Fig. 2d). Despite the transmural inflammation and
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Fig. 1 Neuroradiologic imaging pattern of primary brain amyloidoma. The T1-weighted MRI sequence shows a slightly hypointense right temporal
mass (arrows in a), an ill-defined, moderate gadolinium enhancement (arrows in b), both compatible with malignant glioma. The CT displays small
focal calcifications (arrows in c). The corresponding T2- and FLAIR MRI sequences displayed a hyperintense signal extending beyond the margins of
the contrast enhancement indicating peritumoral edema or an infiltrating part of the mass (arrows in d and e). Almost 2 years following surgical
removal of the PBA, the T1-weighted MRI sequence shows contrast enhancement at the resection margins (arrows in f) compatible with residual
amyloidoma that remained unchanged during the 8-year follow-up
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extensive amyloid deposition, there was no evidence
of a resulting vessel fragility, since intraparenchymal
hemorrhage was virtually absent (Fig. 2e). After iden-
tification of the tumor mass as a cerebral amyloi-
doma, systemic workup including rectal biopsy with
negative results after Congo Red staining and echo-
cardiography revealed no findings suspect for systemic
amyloidosis, thus confirming the diagnosis of a PBA.
Discussion and conclusions
PBA intriguingly share unequivocal features of two trad-
itionally different nosological entities, i.e. cerebral neoplastic
and neurodegenerative disorders. The localized aggregation
of the amyloid in PBA suggests a synthesis of the insoluble
protein at the site of the deposition rather than its leakage
from the vessels [5]. As the amyloid of the cases reported
almost exclusively was found to be of the light chain (AL) λ
type, and in situ hybridization of scattered plasma cells
squeezed between cerebral amyloid masses had shown a
massive preponderance of λ producing cells, the concept to
regard PBA as a low-grade monoclonal B-cell neoplasm
capable of terminal differentiation had been proposed by
Laeng et al. [6], but was later questioned by others [7, 8].
However, the main reason assigning PBA to cerebral neo-
plastic disorders is its progressive space-occupying effect, in
combination with a disrupted BBB mimicking high-grade
glioma [9], but rendering the lesions accessible for surgical
treatment with a benign course thereafter [2, 3, 10]. As yet,
there is only one report on a small recurrent lesion 15 years










Fig. 2 Histopathological and immunohistochemical characteristics of the cerebral amyloidoma. Large concentric sheets of Congo Red stained amyloid
around an arteriole displaying the characteristic apple-green birefringence under polarized light and leading to an extraordinary thickening of the
vessel wall (a), (original magnification × 25). Demonstration of the marked perivascular inflammatory reaction by visualizing macrophages (b) (CD68
immunostaining, original magnification × 200), T-lymphocytes (c), (CD3 immunostaining, original magnification × 100) and B-lymphocytes (d), (CD20
immunostaining, original magnification × 100). Hemosiderin-loaden macrophages indicating previous intraparenchymal microhemorrhage were
encountered only very sporadically (arrows in e), (Prussian blue staining, original magnification × 50)
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Although PBA may be multiple and of variable sizes at
presentation, the aggregates were always locally con-
stricted and no dissemination within the brain was de-
scribed so far, neither radiologically nor in necropsy cases
[2, 5, 6, 11, 12]. Aside from PBA, brain-restricted light
chain (AL) amyloid deposition is found in some different
rare entities, presenting as single or multiple solid masses
in solitary intracerebral plasmacytoma and primary
intracerebral lymphoma with plasmacytic differentiation,
and as disseminated lesions in multiple sclerosis with
demyelination-associated amyloid aggregates, leptomenin-
geal vascular amyloidosis, and widespread subcortical vas-
cular amyloidosis [4, 13, 14]. Since cerebral amyloid
deposits can be associated with systemic amyloidosis, this
has to be ruled by a thorough diagnostic workup [15, 16].
The main pathomorphological finding that underlines
the neurodegenerative character of PBA are the vast
peri- and intravascular amyloid deposits occurring in
vessels adjacent to the parenchymal amyloid masses,
probably reflecting a vascular clearance pathway of the
neurotoxic amyloid by an active transport of the protein
from the adventitial to the luminal side [5, 17]. In con-
trast to sporadic cerebral amyloid angiopathy (CAA),
where the amyloid-ß deposits in the media and
adventitia of cortical and leptomeningeal vessels lead to
vascular fragility and rupture [18], the amyloid accumu-
lations in PBA, though extensive, do not seem to in-
crease the risk for intracerebral bleeding, since
(micro)hemorrhages were virtually absent in the present
case and are also not reported in the literature so far.
Due to the obstruction of parenchymal arterioles in
PBA, local cerebral blood flow and the brain’s trophic sup-
port are severely impaired, disturbing BBB function and
further aggravating the already diminished clearance
mechanisms for the elimination of the insoluble protein
aggregates [19, 20]. The perivascular space in PBA also
houses a plethora of immune cells. Among the
amyloid-induced perivascular inflammatory infiltrate [4],
the abundant perivascular macrophages (PVMs) may act
as scavenger cells to counteract the accumulation of amyl-
oid that has been demonstrated in models of cerebral
amyloid angiopathy [21]. Moreover, PVMs are a major
source of reactive oxygen species. In animal models of Aß
overproduction, the vascular oxidative stress by PVMs has
been identified as a key effector for neurovascular and the
ensuing cognitive dysfunction [22].
The final result of these self-amplifying effects is an
enduring disturbance of the neurovascular unit in brain
Fig. 3 Confocal laser-scanning micrographs of the cerebral amyloidoma. Immunoreactivity for λ-light chain monomers (A) and thioflavin S (ThS)-
stained amyloid in a paraffin section (A´). The overlay in (A´´) shows that the precursors are much more disseminated than their β-pleated self
aggregates (original magnification × 60). Micrograph from a frozen section with thioflavin S-stained amyloid (B), combined with Cy3-immunolabeling
of GFAP in perivascular astroglia (B´) and lectin-staining with Ricinus communis agglutinin (RCA) with Cy5, color-coded in blue (B´´). The allocation of
markers becomes even clearer in the merged picture (B´´´), displaying amyloid deposits in the perivascular space, within the vessel wall and the
vascular lumen (original magnification × 200)
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areas affected by AL-amyloid. Thus, a vicious circle of
hypoxic/ischemic and neurodegenerative pathology
arises, accelerated by the perivascular inflammation. This
coexistence and mutual amplification of neurovascular
dysfunction, inflammation and oxidative stress is detri-
mental to neuronal function and entails cognitive de-
cline and focal neurological signs, as demonstrated for
several forms of cerebral amyloidosis [4].
The histopathological findings of our case support the
hypothesis, that PBA is a rare but unique clinicopatho-
logic entity as it comprises distinct features of both, neo-
plastic and neurodegenerative disorders. Since the
lesions are locally restricted and might be amenable to
surgery, PBA has a prospect of definite cure in contrast
to most other cerebral amyloid disorders.
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